| Issue Date | Title | Author(s) | Type | Мp-cat. |
|---|---|---|---|---|
| 2023 | DNA and RNA Molecules as a Foundation of Therapy Strategies for Treatment of Cardiovascular Diseases![]() | Rakicevic, Ljiljana B | Article | 21aM21a |
| 2023 | Cardiovascular precision medicine – the role of pharmacogenetic testing![]() | Stankov, Karmen | Conference Paper | Mp. category will be shown later |
| 2022 | Matrix metalloproteinase-2 (MMP-2) and-9 (MMP-9) gene variants and microvascular complications in type 2 diabetes patients![]() | Andjelic Jelic, Marina | Article | 23M23 |
| 2022 | Varijante gena "VKORC1" i "CYP2C9" kao farmakogenetički faktori u terapiji acenokumarolom kod bolesnika u Srbiji - razmatranje preosetljivosti i rezistencije![]() | Rakićević, Ljiljana | Article | 23M23 |
| 2021 | The CYP2C19*17 variant is not associated with an increased response to clopidogrel, but it increases the risk for the development of carotid artery stenosis.![]() | Rakicević, Ljiljana | Conference Paper | Mp. category will be shown later |
| 2021 | Pharmacogenetic Biomarkers in Personalized Therapy of Cardiovascular Diseases![]() | Stankov, Karmen | Conference Paper | Mp. category will be shown later |
| 2021 | Analysis of the association of the CYP2C19 variants with the effects of clopidogrel therapy in patients underwent to carotid endarterectomy | Bačković, Dragana; Novković, Mirjana | Conference Paper | Mp. category will be shown later |
| 2021 | Non-coding RNAs as a prospect in diagnostics and treatment of cardiovascular diseases | Rakićević, Ljiljana | Book parts | Mp. category will be shown later |
| 2019 | VARIANT C.454-397T>C OF ESTROGEN RECEPTOR Α INFLUENCES RESULTS OF LUPUS ANTICOAGULANT SCREENING AND FIBRINOGEN MEASURMENT IN PATIENTS WITH ACUTE MYOCARDIAL INAFARCTION - A PILOT STUDY | Rakićević, Ljiljana | Conference Paper | Mp. category will be shown later |
| 2019 | CYP2C19*2 variant is a predictor of poor clopidigrel response and can be base for the economically rationalized antiagregation therapy protocol in Serbian population![]() | Rakicević, Ljiljana
Mitropoulou, C.; van Schaik, R.; Fragoulakis, V.; Vozikis, A.; Patrionos ,G.; Radojković, D.;
| Conference Paper | Mp. category will be shown later |
| 2019 | Pharmacogenetics of Clopidogrel Therapy and Neurointerventional Procedures: We Need Precision Data for Precision Medicine | Rakićević, Ljiljana | Contribution to periodical | 21a+M21a+ |
| 2018 | Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel | Novković, Mirjana | Article | 22M22 |
| 2016 | Uticaj CYP2C19*2 varijante gena na terapijski odgovor u toku primene klopidogrela kod bolesnika sa stenozom karotidne arterije | Bačković, Dragana; Ignjatović, Svetlana | Article | 23M23 |
| 2016 | Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention![]() | Mitropoulou, Christina; Fragoulakis, Vasilios; Rakićević, Ljiljana | Article | 21M21 |
| 2016 | Clopidogrel High On-Treatment Platelet Reactivity in Patients with Carotid Artery Stenosis Undergoing Endarterectomy. A Pilot Study | Backović, Dragana; Ignjatović, Svetlana | Article | 21M21 |
| 2016 | Risk factors for clopidogrel high on-treatment platelet reactivity in patients with carotid artery stenosis undergoing endarterectomy | Backović, D.; Ignjatović, Svetlana | Conference Paper | Mp. category will be shown later |
| 2016 | Differential expression and localization of Ankrd2 isoforms in human skeletal and cardiac muscles![]() | Jasnić, Jovana | Article | 21aM21a |
| 2015 | Pharmacogenetics of antiplatelets and anticoagulants: experience in Serbia![]() | Rakićevic, Liljana
Radak, D.; Radojković, D.;
| Conference Paper | Mp. category will be shown later |
| 2015 | Cardiac Ankyrin Repeat Protein (CARP/Ankrd1/MARP1) Gene Variants in Hypertrophic Cardiomyopathy![]() | Kusic Tisma Jelena | Conference Paper | Mp. category will be shown later |
| 2015 | Cardiac transcription factor Nkx2.5 interacts with p53 and modulates its activity | Kojić, Snežana | Article | 22M22 |